Research
FRAT Program
Research Matching Tool
Syndicated Content
FRAT
Research Matching Tool
Syndicated Content
FORCE designed the only clinical research database and matching tools to help people with inherited mutations fnd and enroll in studies for which they may be eligible by prioritizing studies enrolling people with inherited mutations or relevant biomarkers and summarizing studies, eligibility criteria and titles in plain language, so people can see at a glance what the study is about and for whom it is relevant for.
Our research syndication platform dynamically streams open studies to our partner organizations. Partners can select the trial categories most relevant to their community. Through this program, we will greatly increase exposure and enrollment in these trials.
The FORCE Research Advocate Training (FRAT) program trains constituents to engage in research advocacy on behalf of the hereditary cancer community. Advocates use their personal experiences to help guide hereditary cancer research. FORCE collaborates with researchers who need assistance and matches volunteers to study opportunities based on their cancer status, situation, demographics, experience and the specifc needs of the investigator team.
2024 Priorities
Launch a research-syndicated content platform to disseminate clinical trials and research studies through partners’ sites. Partners can select the trials and studies most relevant to their community. Our initial priority will be recruiting partners focused on underserved and minority populations to increase enrollment in relevant studies. Create a targeted FRAT recruitment plan focused on identifying new volunteers who represent all our constituents, including Black, Indigenous, Asian Pacifc, and Latine people, as well as all people in the LGBTQIA community. Additional recruitment efforts will be placed on people with mutations beyond BRCA and Lynch syndrome.
Proactively connecting with researchers to drive collaborations and increase participant enrollment in studies focused on preventive care, PARP Inhibitors, overcoming targeted therapy drug resistance, rare/deadly hereditary cancers, and studies that address health disparities.
Increase our engagement with researchers during early development to identify gaps in research, provide input into study design, communicate study description, eligibility and study results in plain language .
Made with FlippingBook - professional solution for displaying marketing and sales documents online